Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Ono Outsources Gene Functional Analysis Project to Hitachi
April 9, 2001
- Accurate Information Needed to Overcome Bad Image of Hypnotics: Fujisawa/Sanofi-Synthelabo Seminar
April 9, 2001
- Zeria Aims at \80 Bil. Sales, Net Profit Ratio of 10% in 2005
April 9, 2001
- Taisho, Arena Tie Up for GPCR Discovery Research
April 9, 2001
- Amended Commercial Law to Accelerate Drug Industry Reorganization:Ihoken
April 9, 2001
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
April 9, 2001
- OTC News in Brief
April 9, 2001
- REGULATORY NEWS IN BRIEF -2-
April 9, 2001
- Aiming at Top 5 between 2005 and 2010: Mr Dunoyer of GSK
April 9, 2001
- REGULATORY NEWS IN BRIEF -1-
April 9, 2001
- Shimadzu, Eisai Codevelop Washing Validation Support System
April 9, 2001
- Sysmex Opens Technical Service Center in Africa
April 9, 2001
- Lysosome Disease Added as Designated Disease
April 9, 2001
- Yamanouchi Wants to Make Lipitor No. 1 Statin in Japan
April 9, 2001
- Final Draft of Ethical Guidelines for Human Genome Research Approved
April 2, 2001
- Sankyo Ties Up with Menarini to Market CS-866 in Europe
April 2, 2001
- 'Number System' Proposed for Social Security
April 2, 2001
- Celera to Acquire Minority Interest in HuBit Genomix
April 2, 2001
- Radicut, Herceptin, Zyvox Approved by CDFS
April 2, 2001
- DIAGNOSTIC NEWS IN BRIEF
April 2, 2001
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…